We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
PHE have updated their guidance
(previously 2013) on the use of tetanus immunoglobulin (TIG) and human normal immunoglobulin (HNIG) for treatment of post exposure tetanus-prone injuries, in response to evidence of a severe shortage of both TIG and HNIG within the NHS. The revised guidance has reviewed exsiting data and evidence to prioritise the use of TIG and HNIG for susceptible individuals with high risk injuries, over those where a booster of tetanus vaccine is appropriate.
